Key Takeaways
- On August 18, CEO Jason Hollar offloaded 124,529 shares of CAH stock valued at $29.4 million, marking his first such transaction since August 2025
- Executive-level insider sales totaled approximately $60 million in the period immediately after the earnings announcement
- The stock reached an all-time closing high of $240.26 on August 11 following fourth-quarter earnings per share of $2.91, surpassing the consensus forecast of $2.42
- Shares have retreated from their peak, beginning Friday’s session at $229.48 after touching $258.30 during intraday trading
- Wall Street consensus leans toward “Moderate Buy” with analysts projecting an average target price of $266.56
In a significant move, Cardinal Health CEO Jason Hollar divested $29.4 million in company shares on August 18, merely one week after the healthcare giant celebrated unprecedented gains driven by impressive quarterly results. The stock achieved a historic closing price of $240.26 on August 11 and surged to an intraday peak of $258.30.
Hollar’s transactions occurred at share prices ranging from $234.07 to $238.065. This represented his initial open-market divestiture since August 2025 and just the second time he has sold company stock since his appointment at Cardinal in 2020.
The CEO wasn’t operating in isolation. A coordinated wave of stock sales rippled through the senior leadership team on the identical date, culminating in aggregate transactions approaching $60 million.
Chief Financial Officer Aaron Alt disposed of 42,000 shares, generating proceeds exceeding $9.9 million. Jessica Mayer, serving as Chief Legal and Compliance Officer, sold 29,436 shares worth approximately $7 million. Michelle Greene, the Chief Information Officer, liquidated 11,650 shares for $2.7 million.
Division Leaders Join Selling Spree
Leadership of Cardinal’s primary operating divisions similarly reduced their shareholdings. Debbie Weitzman, heading the pharmaceutical division, sold 7,354 shares generating roughly $1.7 million. Steve Mason, who leads the global medical products and distribution segment, divested 35,000 shares worth approximately $8.3 million, reducing his ownership position by nearly two-thirds.
Chief Accounting Officer Mary Scherer sold 2,302 shares on August 19 for about $546,472. Collectively, company insiders sold 210,271 shares valued at approximately $49.6 million during the most recent quarter.
This selling activity followed Cardinal’s August 11 fourth-quarter earnings announcement that significantly exceeded expectations. The company reported earnings per share of $2.91, substantially above the Street consensus of $2.42. Revenue climbed 5.8% compared to the prior year, reaching $63.67 billion, though falling slightly short of analyst projections of $65.15 billion.
Management also provided fiscal 2027 EPS guidance ranging from $12.40 to $12.60, which catalyzed the stock’s initial rally. Current analyst consensus anticipates full-year earnings per share of $12.54.
Wall Street Maintains Optimistic Outlook
Notwithstanding the recent price decline and substantial insider transactions, analyst sentiment remains predominantly favorable. TD Cowen elevated its price objective to $280 while reaffirming a “buy” recommendation. Leerink Partners established a $292 price target. Royal Bank of Canada commenced coverage with an “outperform” designation and a $276 objective.
JPMorgan increased its target from $215 to $260 while maintaining a “neutral” stance. Sixteen analysts recommend buying the stock, with three advocating a hold position. The consensus price target stands at $266.56.
On Friday, CAH shares opened at $229.48, representing a decline from the post-earnings pinnacle. The 12-month low sits at $145.87. The company announced a quarterly dividend of $0.5158 per share, scheduled for October 15 distribution to shareholders registered as of October 1, yielding 0.9%.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
